Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 22, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/22/14 - "Intravenous Formulation with Water-Soluble Cocrystals of Acetylsalicylic Acid and Theanine" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Brittain, Harry G.; Felice, Philip V., filed on May 21, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Theaprin Pharmaceutic
10/22/14 - Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
DUBLIN and BOSTON, Oct. 22, 2014/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin, a peptide ghrelin agonist, for t
10/22/14 - Alkermes New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Alkermes plc today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for aripiprazole lauroxil, the company s investigational, novel, once-monthly injectable atypical antipsychotic for the treatment of schizophrenia. Under the Prescription Drug User Fee Act, the FDA s target action date for
10/22/14 - ALS ACT, The ALS Association, and the Northeast ALS Consortium Issue Request for Proposals for Phase II Clinical Development of Novel, High-Potential Treatments for ALS
WASHINGTON, Oct. 22, 2014/ PRNewswire-USNewswire/ ALS ACT, The ALS Association, and the T ranslational Re search A dvancing T herapy ALS Northeast ALS Consortium clinical trials network are pleased to announce a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis. The call for clinic
10/22/14 - AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode
AVACEN Medical announced today that its AVACEN 100 Class II medical device received 510 OTC clearance by the U.S. Food and Drug Administration. This clearance allows the AVACEN 100 to be marketed over the Internet for: the temporary relief of joint pain associated with arthritis; muscle spasms; and minor strains and sprains. In' Game Mode,' the t
10/22/14 - Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
Under the terms of the agreement, Bavarian Nordic will grant Janssen an exclusive license for its multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus. In addition, Bavarian Nordic will scale up its production and is targeting to manufacture more than 1 million doses of the vaccine valued at U
10/22/14 - Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN Ebola Vaccine
*Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson& Johnson licenses MVA-BN-based Ebola/ Marburg vaccine from Bavarian Nordic* Bavarian Nordic will scale up and is targeting to manufacture more than 1 million doses of the prophylactic vaccine in 2015 for clinical trials and emergency use in the current Ebola outbreak in W
10/22/14 - Biocon Q2 FY15 Revenues at 773 Crore, PAT at 102 Crore [Global Data Point]
?Biocon's partner Mylan begins multicenter phase III clinical trials for insulin glargine in the United States.? Biocon, through its subsidiary Biocon Research Limited, buys back GE Equity International Mauritius' s 7.69% stake in Syngene for Rs. 215.38 Crore. Subsequently, it enters into an agreement to sell 10% to Silve r Leaf Oak Limited, va
10/22/14 - Bristol-Myers Squibb Statement about Asunaprevir in the U.S.
By a News Reporter-Staff News Editor at Biotech Week Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1 b patients in the United States and
10/22/14 - Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on October 29, 2014
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report third quarter 2014 financial results after the close of U.S. financial markets on October 29, 2014. Cempra management will host a webcast and.
10/22/14 - CTRC doctor wins $1.6 million FDA orphan grant to treat deadly brain tumors
By a News Reporter-Staff News Editor at Biotech Week A researcher at the Cancer Therapy& Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food& Drug Administration. The FDA's four-year grant will allow Andrew Brenner, M.D., Ph.D. to continue the study how the drug TH-302 may help people with
10/22/14 - Data on Head and Neck Cancer Reported by Researchers at Department of Surgery [Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or...
Data on Head and Neck Cancer Reported by Researchers at Department of Surgery. According to news originating from New York City, New York, by NewsRx correspondents, research stated, "We previously reported inferior outcomes for locally-advanced head and neck squamous cell carcinoma patients treated with concurrent cetuximab vs. high-dose cisplatin
10/22/14 - FDA Grants Clearance to Proceed with Clinical Study - New Drug Candidate from Vivolux Could Overcome Drug Resistance
By a News Reporter-Staff News Editor at Biotech Week Vivolux, a pharmaceutical company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX1570 to clinical phase I/II for treatment against relapsed and/or refractory multiple myeloma. The clinical study will be conducted in collaboration with the Memori
10/22/14 - Flexion Therapeutics, Inc. (Nasdaq: FLXN) to Ring The Nasdaq Stock Market Opening Bell
Flexion Therapeutics, Inc., a specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, will visit the Nasdaq MarketSite in Times Square. Nasdaq MarketSite 4 Times Square 43 rd& Broadway Broadcast Studio. Flexion Therapeutics, Inc. Media Contact: Lisa Davidson 305-7765...
10/22/14 - GeoVax to Present HIV Vaccine Clinical Trial Data at HIVR4P Conference
ATLANTA, GA/ ACCESSWIRE/ October 22, 2014/ GeoVax Labs, Inc., a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will give an oral presentation at the HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and A
10/22/14 - GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Designation From European Medicines Agency for the Treatment of Dravet Syndrome
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency has granted orphan designation to GW's investigational product Epidiolex in the treatment of Dravet syndrome, a rare.
10/22/14 - Gynesonics Receives FDA Approval to Commence a Pivotal IDE Clinical Trial for the Newly-Designed Vizablate System
Gynesonics, Inc., a women s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced it has received approval from the U.S. Food and Drug Administration of an investigational device exemption for the pivotal trial, Sonography Guided Transcervical Ablation of Uterine Fibroids,
10/22/14 - Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences
By a News Reporter-Staff News Editor at Biotech Week Halozyme Therapeutics, Inc. announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of Sciences symposium "Targeting Key Vulnerabilities in Pancreatic Cancer," being held on October 9, 2014 in New York City. "These data in animal models support our ongoing Phase 2
10/22/14 - IBC Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 22 IBC Pharmaceuticals, Morris Plains, New Jersey, has been assigned a patent developed by four co-inventors for "methods and compositions for generating bioactive assemblies of increased complexity and uses." The co-inventors are Chien-Hsing Chang, Downingtown, Pennsylvania, David M. Goldenberg, Mendham, New Jersey, William
10/22/14 - Insys Gets DEA Approval to Produce Pharmaceutical Cannabidiol; Posts Status of Its Cannabinoid Program [Professional Services Close - Up]
Insys Therapeutics, Inc. reported that its Food and Drug Administration inspected and Drug Enforcement Agency approved facility in Round Rock, Texas, has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol. Insys believes these quantities are sufficient to pursue its CBD development program as currently planned.
10/22/14 - Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
Johnson& Johnson today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The vaccine regimen, which was discovered in a collaborative research program with the National Institutes of Health, combine
10/22/14 - Masimo Updates on Clinical Study [Professional Services Close - Up]
Masimo reported that a new clinical study evaluating Masimo's latest noninvasive patient monitoring parameter, Oxygen Reserve Index ORI, showed that ORI can provide advanced warning of potential hypoxia and may help clinicians optimize oxygenation before and during prolonged intubation. At the University of Texas Southwestern and Children's Medical
10/22/14 - Masimo Updates on New Clinical Study [Professional Services Close - Up]
Masimo reported that a new clinical study evaluating Masimo's latest noninvasive patient monitoring parameter, Oxygen Reserve Index ORI, showed that ORI can provide advanced warning of potential hypoxia and may help clinicians optimize oxygenation before and during prolonged intubation. At the University of Texas Southwestern and Children's Medical
10/22/14 - Medicines Co. beats 3Q earnings expectations
PARSIPPANY, N.J. - The Medicines Co. on Wednesday reported a loss of $16.7 million in its third quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. Analysts expected $191 million, according to Zacks.
10/22/14 - Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2014 before the U.S. financial markets open on Wednesday, November 5, 2014. Our logo, trademarks, and service marks are the property of Momenta..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415